Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS.

Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18.

3.

The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study.

Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, Cartlidge S, Paterson D, Copley C, Kendrew J, Barnes C, Harris AL, Gatter KC.

Histopathology. 2003 Jul;43(1):33-9.

PMID:
12823710
4.

McTimoney chiropractic: a gentle way with back pain.

Cartlidge S.

Complement Ther Nurs Midwifery. 1997 Oct;3(5):136-41. Review.

PMID:
9432435
5.

Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase.

Breeze AL, Kara BV, Barratt DG, Anderson M, Smith JC, Luke RW, Best JR, Cartlidge SA.

EMBO J. 1996 Jul 15;15(14):3579-89.

6.

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.

Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR.

Breast Cancer Res Treat. 1996;38(1):67-73. Review.

PMID:
8825124
7.
8.

Substrate selection and processing in endocytosis.

Lloyd JB, Pratten MK, Duncan R, Kooistra T, Cartlidge SA.

Biochem Soc Trans. 1984 Dec;12(6):977-8. No abstract available.

PMID:
6530046

Supplemental Content

Loading ...
Support Center